Emma Eckernäs

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Multiple Sclerosis

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical and translational science

Journal of psychopharmacology (Oxford, England)

Molecular pharmaceutics

This page only lists publications with an associated author ORCID identifier.

Publications

Emma Eckernäs, Jeroen Koomen, Christopher Timmermann, Robin Carhart-Harris, Daniel Röshammar, Michael Ashton
Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework. CPT: pharmacometrics & systems pharmacology (2023)
Emma Eckernäs, Christopher Timmermann, Robin Carhart-Harris, Daniel Röshammar, Michael Ashton
N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner-A pharmacokinetic/pharmacodynamic analysis. CPT: pharmacometrics & systems pharmacology (2023)
S Parker Singleton, Christopher Timmermann, Andrea I Luppi, Emma Eckernäs, Leor Roseman, Robin Lester Carhart-Harris, Amy F Kuceyeski
Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience. bioRxiv : the preprint server for biology (2023)
Lisa X Luan, Emma Eckernäs, Michael Ashton, Fernando E Rosas, Malin V Uthaug, Alexander Bartha, Samantha Jagger, Kiara Gascon-Perai, Lauren Gomes, David J Nutt, David Erritzøe, Robin Lester Carhart-Harris, Christopher Timmermann
Psychological and physiological effects of extended DMT. Journal of psychopharmacology (Oxford, England) (2023)
Emma Eckernäs, Christopher Timmermann, Robin Carhart-Harris, Daniel Röshammar, Michael Ashton
Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine - Implications for dose considerations. Clinical and translational science (2022)
Emma Eckernäs, Christer Tannergren
Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs. Molecular pharmaceutics 18 (4) (2021)